Dr. Benjamin Paluch
Recent Articles about Replimune Group Inc.
MA Biotech Reports Positive Meeting with FDA 09/09/2024
Replimune Group Inc.'s (REPL:NASDAQ) announced a successful pre-Biologics License Application (BLA) meeting with the FDA, according to a Roth MKM research note.
© 2025 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
